Atsena Therapeutics, founded with a mission to leverage genetic medicine to reverse or prevent blindness, is a clinical-stage gene therapy company. Their core focus is on developing innovative treatments for inherited retinal diseases. Atsena's pipeline includes therapies for conditions such as Leber Congenital Amaurosis 1 (LCA1), X-linked Retinoschisis (XLRS), and Usher Syndrome Type 1B (USH1B). The company employs advanced technologies like laterally spreading capsids and dual vector technology to enhance the delivery and efficacy of their gene therapies.

Notable figures affiliated with Atsena Therapeutics include experts on their Clinical and Scientific Advisory Boards, who bring significant experience in ophthalmology and genetic research. The company has garnered attention from prominent investors and partners in the biotech sector. A key achievement is their ongoing Phase I/II clinical trial for LCA1, which demonstrates their commitment to advancing treatments for inherited blindness. Atsena's work has the potential to significantly impact patients' lives by restoring vision and improving quality of life for those affected by genetic ocular conditions.